Barclays analyst Matt Miksic raised the firm’s price target on Stryker to $265 from $257 and keeps an Overweight rating on the shares. The macro backdrop remains challenging for medical supplies and devices and the timing for improvements in inflationary pressures, supply chain issues and hospital staffing challenges is uncertain, Miksic tells investors in a research note. However, the analyst remains "generally constructive" on the sector, seeing improving volume trends, stable staffing challenges, and "potentially stabilizing" supply chain and inflationary cost trends. He continues to favor names with operating leverage or "discontinuous and favorable tailwinds, as they are generally better positioned to weather higher input costs."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SYK:
- Stryker price target raised to $265, added to ‘TAP Outperform’ list at Evercore
- Hedge Funds Are Pouring Money into Stryker (NYSE:SYK) Stock
- Stryker to host conference call on January 31, 2023
- Stryker price target raised to $268 from $232 at BTIG
- Stryker price target raised to $283 from $233 at Cowen